This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Oakley, K. L.
Right arrow Articles by Denning, D. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Oakley, K. L.
Right arrow Articles by Denning, D. W.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, October 1998, p. 2726-2730, Vol. 42, No. 10
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

In Vitro Activity of the Echinocandin Antifungal Agent LY303,366 in Comparison with Itraconazole and Amphotericin B against Aspergillus spp.

Karen L. Oakley,1 Caroline B. Moore,2 and David W. Denning1,3,*

Departments of Medicine1 and Microbiology,2 Hope Hospital, and University of Manchester,3 Manchester, United Kingdom

Received 24 November 1997/Returned for modification 27 January 1998/Accepted 15 July 1998

LY303,366 (LY) is a novel derivative of the echinocandin class of antifungal agents. The in vitro activities of LY, itraconazole (ITZ), and amphotericin B (AMB) were assessed against 60 Aspergillus isolates, including 35 isolates of A. fumigatus, eight isolates of A. terreus, eight isolates of A. flavus, eight isolates of A. niger and one isolate of A. nidulans. Four A. fumigatus isolates were resistant to ITZ. Susceptibility testing for all drugs was performed with a broth microdilution procedure. LY was tested in two media: antibiotic medium 3 (AM3) and Casitone with 2% glucose (CAS) with an inoculum of 2 × 103 spores/ml. ITZ and AMB were tested in RPMI 1640 with 2% glucose with an inoculum of 1 × 106 spores/ml. All tests were incubated at 37°C for 48 h. A novel end point was used to determine a minimal effective concentration (MEC) for LY, i.e., almost complete inhibition of growth save a few tiny spherical colonies attached to the microplate. MICs were measured for ITZ and AMB with a no-growth end point. Ranges and geometric mean (GM) MECs were from 0.0018 to >0.5 and 0.0039 mg/liter and from 0.0018 to >0.5 and 0.008 mg/liter for LY in AM3 and LY in CAS, respectively. Differences between species were apparent, with A. flavus being significantly less susceptible to LY than any other species tested with both media (P <=  0.05). Ranges and GM MICs were from 0.125 to >16 and 0.7 mg/liter for ITZ and from 0.25 to 16 and 1.78 mg/liter for AMB. Minimal fungicidal concentrations (MFCs) were also determined for all drugs. GM MFCs were 0.018, 0.09, 19.76, and 12.64 mg/liter for LY in AM3, LY in CAS, ITZ, and AMB, respectively. LY in AM3 and LY in CAS were fungicidal for 86.7 and 68% of isolates, respectively (98% killing). In comparison, ITZ and AMB were fungicidal for 35 and 70% of isolates, respectively (99.99% killing). A reproducibility study was performed on 20% of the isolates. For 12 isolates retested, the MEC or MIC was the same or was within 1 dilution of the original value for 11, 11, 10, and 9 isolates for LY in AM3, LY in CAS, ITZ, and AMB, respectively. In conclusion, LY seems to be a promising antifungal agent with excellent in vitro activity against Aspergillus spp.

* Corresponding author. Present address: Department of Infectious Diseases and Tropical Medicine (Monsall Unit), North Manchester General Hospital, Delauneys Rd., Manchester, M8 6RB, United Kingdom. Phone: 44 161 720 2734. Fax: 44 161 720 2732.

Antimicrobial Agents and Chemotherapy, October 1998, p. 2726-2730, Vol. 42, No. 10
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Hedayati, M. T., Pasqualotto, A. C., Warn, P. A., Bowyer, P., Denning, D. W. (2007). Aspergillus flavus: human pathogen, allergen and mycotoxin producer. Microbiology 153: 1677-1692 [Abstract] [Full Text]  
  • Khan, Z. U., Ahmad, S., Mokaddas, E., Said, T., Nair, M. P., Halim, M. A., Nampoory, M. R., McGinnis, M. R. (2007). Cerebral aspergillosis diagnosed by detection of Aspergillus flavus-specific DNA, galactomannan and (1->3)-{beta}-D-glucan in clinical specimens. J Med Microbiol 56: 129-132 [Abstract] [Full Text]  
  • Messer, S. A., Kirby, J. T., Sader, H. S., Fritsche, T. R., Jones, R. N. (2004). Initial results from a longitudinal international surveillance programme for anidulafungin (2003). J Antimicrob Chemother 54: 1051-1056 [Abstract] [Full Text]  
  • Odabasi, Z., Paetznick, V. L., Rodriguez, J. R., Chen, E., Ostrosky-Zeichner, L. (2004). In Vitro Activity of Anidulafungin against Selected Clinically Important Mold Isolates. Antimicrob. Agents Chemother. 48: 1912-1915 [Abstract] [Full Text]  
  • Warn, P. A., Sharp, A., Guinea, J., Denning, D. W. (2004). Effect of hypoxic conditions on in vitro susceptibility testing of amphotericin B, itraconazole and micafungin against Aspergillus and Candida. J Antimicrob Chemother 53: 743-749 [Abstract] [Full Text]  
  • Serena, C., Ortoneda, M., Capilla, J., Pastor, F. J., Sutton, D. A., Rinaldi, M. G., Guarro, J. (2003). In Vitro Activities of New Antifungal Agents against Chaetomium spp. and Inoculum Standardization. Antimicrob. Agents Chemother. 47: 3161-3164 [Abstract] [Full Text]  
  • Arevalo, M. P., Carrillo-Munoz, A.-J., Salgado, J., Cardenes, D., Brio, S., Quindos, G., Espinel-Ingroff, A. (2003). Antifungal activity of the echinocandin anidulafungin (VER002, LY-303366) against yeast pathogens: a comparative study with M27-A microdilution method. J Antimicrob Chemother 51: 163-166 [Abstract] [Full Text]  
  • Denning, D. W. (2002). Echinocandins: a new class of antifungal. J Antimicrob Chemother 49: 889-891 [Full Text]  
  • Groll, A. H., Mickiene, D., Petraitiene, R., Petraitis, V., Lyman, C. A., Bacher, J. S., Piscitelli, S. C., Walsh, T. J. (2001). Pharmacokinetic and Pharmacodynamic Modeling of Anidulafungin (LY303366): Reappraisal of Its Efficacy in Neutropenic Animal Models of Opportunistic Mycoses Using Optimal Plasma Sampling. Antimicrob. Agents Chemother. 45: 2845-2855 [Abstract] [Full Text]  
  • Roberts, J., Schock, K., Marino, S., Andriole, V. T. (2000). Efficacies of Two New Antifungal Agents, the Triazole Ravuconazole and the Echinocandin LY-303366, in an Experimental Model of Invasive Aspergillosis. Antimicrob. Agents Chemother. 44: 3381-3388 [Abstract] [Full Text]  
  • Chiou, C. C., Groll, A. H., Walsh, T. J. (2000). New Drugs and Novel Targets for Treatment of Invasive Fungal Infections in Patients with Cancer. The Oncologist 5: 120-135 [Abstract] [Full Text]  
  • Ikeda, F., Wakai, Y., Matsumoto, S., Maki, K., Watabe, E., Tawara, S., Goto, T., Watanabe, Y., Matsumoto, F., Kuwahara, S. (2000). Efficacy of FK463, a New Lipopeptide Antifungal Agent, in Mouse Models of Disseminated Candidiasis and Aspergillosis. Antimicrob. Agents Chemother. 44: 614-618 [Abstract] [Full Text]  
  • Tawara, S., Ikeda, F., Maki, K., Morishita, Y., Otomo, K., Teratani, N., Goto, T., Tomishima, M., Ohki, H., Yamada, A., Kawabata, K., Takasugi, H., Sakane, K., Tanaka, H., Matsumoto, F., Kuwahara, S. (2000). In Vitro Activities of a New Lipopeptide Antifungal Agent, FK463, against a Variety of Clinically Important Fungi. Antimicrob. Agents Chemother. 44: 57-62 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»